Analyst Ratings For NASDAQ:CTRV – ContraVir Pharmaceuticals (NASDAQ:CTRV)
Today, Maxim Group reiterated its Hold rating on NASDAQ:CTRV – ContraVir Pharmaceuticals (NASDAQ:CTRV).
Some recent analyst ratings include
- 4/13/2018-Maxim Group Reiterated Rating of Hold.
- 4/21/2017-Noble Financial Reiterated Rating of Buy.
- 6/1/2016-ING Group initiated coverage with a Positive rating.
Recent Insider Trading Activity For NASDAQ:CTRV – ContraVir Pharmaceuticals (NASDAQ:CTRV)
NASDAQ:CTRV – ContraVir Pharmaceuticals (NASDAQ:CTRV) has insider ownership of 4.30% and institutional ownership of 8.16%.
- On 6/20/2017 John T Cavan, CFO, bought 20,000 with an average share price of $0.65 per share and the total transaction amounting to $13,000.00.
- On 2/18/2016 James Sapirstein, CEO, bought 10,000 with an average share price of $1.00 per share and the total transaction amounting to $10,000.00.
- On 11/23/2015 James Sapirstein, CEO, bought 2,500 with an average share price of $1.64 per share and the total transaction amounting to $4,100.00.
- On 3/4/2014 John P Brancaccio, Director, bought 4,393 with an average share price of $1.49 per share and the total transaction amounting to $6,545.57.
Recent Trading Activity for NASDAQ:CTRV – ContraVir Pharmaceuticals (NASDAQ:CTRV)
Shares of NASDAQ:CTRV – ContraVir Pharmaceuticals closed the previous trading session at 0.28 +0.00 1.61% with 0.30000001192092896 shares trading hands.